NeoRx settles investor lawsuits

Article

Monoclonal antibody developer NeoRx of Seattle last month settled a lawsuit filed against it by shareholders.The litigation was related to a public stock offering made byNeoRx in December 1993 (SCAN 6/15/94). The settlement is for stockor a combination

Monoclonal antibody developer NeoRx of Seattle last month settled a lawsuit filed against it by shareholders.The litigation was related to a public stock offering made byNeoRx in December 1993 (SCAN 6/15/94). The settlement is for stockor a combination of stock and cash worth $1.5 million. A substantialportion of the settlement will be covered by insurance, the companysaid.

NeoRx last month also reported its financial results for 1994(end-December). The company reported a net loss of $11.1 millionon revenues of $1.6 million for the year, compared to a net lossof $8.5 million and revenues of $3.7 million in 1993.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.